Application of injectable hydrogels in immunotherapy via the cGAS-STING pathway for cancer and inflammatory disease treatment
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: interferon and immune responses · Ubiquitin and proteasome pathways · Immune responses and vaccinations
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Immunotherapy of cancer in 2012
2. Molecular mechanisms and cellular functions of cGAS–STING signalling10.1038/s41580-020-0244-x ↗
3. The gut microbiota prime systemic antiviral immunity via the cGAS-STING-IFN-I axis10.1016/j.immuni.2022.04.006 ↗
4. cGAS-STING pathway in cancer biotherapy10.1186/s12943-020-01247-w ↗
5. cGAS–STING drives ageing-related inflammation and neurodegeneration10.1038/s41586-023-06373-1 ↗
6. Engineering and delivery of cGAS-STING immunomodulators for the immunotherapy of cancer and autoimmune diseases10.1021/acs.accounts.3c00394 ↗
7. Delivery technologies for cancer immunotherapy10.1038/s41573-018-0006-z ↗
8. Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy10.1038/s41401-020-0400-z ↗
9. Smart injectable hydrogels for cancer immunotherapy10.1002/adfm.201902785 ↗
10. Functional hydrogel coatings10.1093/nsr/nwaa254 ↗
11. Adaptable microporous hydrogels of propagating NGF‐gradient by injectable building blocks for accelerated axonal outgrowth10.1002/advs.201900520 ↗
12. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling10.1038/nature07317 ↗
13. The adaptor protein MITA links virus-sensing receptors to IRF3 transcription factor activation10.1016/j.immuni.2008.09.003 ↗
14. Regulating STING in health and disease10.1186/s12950-017-0159-2 ↗
15. STING is adirect innate immune sensor of cyclic di-GMP10.1038/nature10429 ↗
16. ERIS, an endoplasmic reticulum IFN stimulator, activates innate immune signaling through dimerization10.1073/pnas.0900850106 ↗
17. The ubiquitin ligase TRIM56regulates innate immune responses to intracellular double-stranded DNA10.1016/j.immuni.2010.10.013 ↗
18. STING specifies IRF3 phosphorylation byTBK1 in the cytosolic DNA signaling pathway10.1126/scisignal.2002521 ↗
19. The ubiquitin ligase RNF5 regulates antiviral responses by mediating degradation of the adaptor protein MITA10.1016/j.immuni.2009.01.008 ↗
20. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway10.1126/science.1232458 ↗
21. TBK1 recruitment to STING activates both IRF3 and NF-κB that mediate immune defense against tumors and viral infections10.1073/pnas.2100225118 ↗
22. Interaction between the SFTSV envelope glycoprotein Gn and STING inhibits the formation of the STING-TBK1 complex and suppresses the NF-κB signaling pathway10.1128/jvi.01815-23 ↗
23. The STING in the tail for cytosolic DNA–dependent activation of IRF310.1126/scisignal.2002919 ↗
24. Group A streptococcus activates type I interferon production and MyD88-dependent signaling without involvement of TLR2, TLR4, and TLR910.1074/jbc.M802848200 ↗
25. Streptococcus pneumoniae DNA initiates type I interferon signaling in the respiratory tract10.1128/mBio.00016-11 ↗
26. Stimulator of IFN gene is critical for induction of IFN-β during chlamydia muridarum infection10.4049/jimmunol.0903704 ↗
27. The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling10.1016/j.molcel.2014.03.040 ↗
28. Crystal structures of STING protein reveal basis for recognition of cyclic di-GMP10.1038/nsmb.2332 ↗
29. Cryo-EM structures of STING reveal its mechanism of activation by cyclic GMP–AMP10.1038/s41586-019-0998-5 ↗
30. Ubiquitination of STING at lysine 224 controls IRF3 activation10.1126/sciimmunol.aah7119 ↗
31. Activation of STING requires palmitoylation at the Golgi10.1038/ncomms11932 ↗
32. iRhom2 is essential for innate immunity to DNA viruses by mediating trafficking and stability of the adaptor STING10.1038/ni.3510 ↗
33. TBK1 recruitment to STING activates both IRF3 and NF-κB that mediate immune defense against tumors and viral infections10.1073/pnas.2100225118 ↗
34. STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway10.1126/scisignal.2002521 ↗
35. STING recognition of cytoplasmic DNA instigates cellular defense10.1016/j.molcel.2013.01.039 ↗
36. Recognition of cytosolic DNA activates an IRF3-dependent innate immune response10.1016/j.immuni.2005.12.003 ↗
37. Innate immune sensing and signaling of cytosolic nucleic acids10.1146/annurev-immunol-032713-120156 ↗
38. Chemical and biomolecular strategies for STING pathway activation in cancer immunotherapy10.1021/acs.chemrev.1c00750 ↗
39. STING: a master regulator in the cancer-immunity cycle10.1186/s12943-019-1087-y ↗
40. The multifaceted functions of cGAS10.1093/jmcb/mjac031 ↗
41. Oxidized mitochondrial DNA activates the cGAS-STING pathway in the neuronal intrinsic immune system after brain ischemia-reperfusion injury10.1016/j.neurot.2024.e00368 ↗
42. ER-Phagy and microbial infection
43. Regulation and function of the cGAS–STING pathway of cytosolic DNA sensing10.1038/ni.3558 ↗
44. DNA sensing by the cGAS–STING pathway in health and disease10.1038/s41576-019-0151-1 ↗
45. Balancing STING in antimicrobial defense and autoinflammation10.1016/j.cytogfr.2020.06.004 ↗
46. Tumor-derived cGAMP triggers a STING-mediated interferon response in non-tumor cells to activate the NK cell response10.1016/j.immuni.2018.09.016 ↗
47. Exosomes shuttle TREX1-sensitive IFN-stimulatory dsDNA from irradiated cancer cells to DCs10.1158/2326-6066.CIR-17-0581 ↗
48. The TREX1 exonuclease R114H mutation in Aicardi-Goutières syndrome and lupus reveals dimeric structure requirements for DNA degradation activity10.1074/jbc.M111.297903 ↗
49. Principles of cancer therapy: Oncogene and non-oncogene addiction10.1016/j.cell.2009.02.024 ↗
50. Mesenchymal stromal cells increase the natural killer resistance of circulating tumor cells via intercellular signaling of cGAS‐STING‐IFNβ‐HLA10.1002/advs.202400888 ↗
51. STING agonists and how to reach their full potential in cancer immunotherapy10.1002/advs.202500296 ↗
52. miR-25/93 mediates hypoxia-induced immunosuppression by repressing cGAS10.1038/ncb3615 ↗
53. Cancer vaccines: current status and future directions10.1186/s13045-025-01670-w ↗
54. Casey · 2015 · vol. 35 · S199
55. Type I IFNs control antigen retention and survival of CD8α+ dendritic cells after uptake of tumor apoptotic cells leading to cross-priming10.4049/jimmunol.1004163 ↗
56. Tumor cGAMP awakens the natural killers10.1016/j.immuni.2018.10.001 ↗
57. Systemic activation of dendritic cells by toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity10.1038/ni1300 ↗
58. cGAS is essential for the antitumor effect of immune checkpoint blockade10.1073/pnas.1621363114 ↗
59. STING is crucial for the survival of RUNX1:: RUNX1T1 leukemia cells10.1038/s41375-024-02383-8 ↗
60. DNA methyltransferase inhibitors: catalysts for antitumour immune responses10.2147/OTT.S217767 ↗
61. Bioinformatic characterization of STING expression in hematological malignancies reveals association with prognosis and anti-tumor immunity
62. STING activation improves T-cell-engaging immunotherapy for acute myeloid leukemia10.1182/blood.2024026934 ↗
63. Cytoplasmic Escape of mitochondrial DNA mediated by Mfn2 downregulation promotes microglial activation via cgas-sting axis in spinal cord injury
64. Discovery of STING antagonists targeting cGAS-STING pathway to alleviate IMQ-induced psoriasis-like dermatitis
65. STING in tumors: a focus on non-innate immune pathways10.3389/fcell.2023.1278461 ↗
66. Deregulated NLRP3 and NLRP1 inflammasomes and their correlations with disease activity in systemic lupus erythematosus10.3899/jrheum.130310 ↗
67. cGAS-STING pathway in pathogenesis and treatment of osteoarthritis and rheumatoid arthritis
68. Centromere defects, chromosome instability, and cGAS-STING activation in systemic sclerosis10.1038/s41467-022-34775-8 ↗
69. Signaling by cGAS–STING in neurodegeneration, neuroinflammation, and aging10.1016/j.tins.2020.10.008 ↗
70. Licorice extract inhibits the cGAS-STING pathway and protects against non-alcoholic steatohepatitis10.3389/fphar.2023.1160445 ↗
71. Roles of JAK2 in aging, inflammation, hematopoiesis and malignant transformation10.3390/cells8080854 ↗
72. Research progress on the cGAS-STING signaling pathway in immune-mediated inflammatory diseases in children
73. STING and liver disease10.1007/s00535-021-01803-1 ↗
74. Connexin 43 deficiency confers resistance to immunotherapy in lung cancer via inhibition of the cyclic GMP‐AMP synthase–stimulator of Interferon genes pathway10.1111/jcmm.70211 ↗
75. c-di-AMP secreted by intracellular Listeria monocytogenes activates a host type I interferon response10.1126/science.1189801 ↗
76. Environmentally responsive hydrogel promotes vascular normalization to enhance STING anti-tumor immunity10.1016/j.jconrel.2024.06.052 ↗
77. Magnitude of therapeutic STING activation determines CD8+ T cell-mediated anti-tumor immunity10.1016/j.celrep.2018.11.047 ↗
78. Synthesis and immunostimulatory properties of the phosphorothioate analogues of cdiGMP10.1016/j.bmcl.2008.08.088 ↗
79. Hydrolysis of 2′ 3′-cGAMP by ENPP1 and design of nonhydrolyzable analogs10.1038/nchembio.1661 ↗
80. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity10.1016/j.celrep.2015.04.031 ↗
81. STING pathway agonism as a cancer therapeutic10.1111/imr.12765 ↗
82. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy10.1038/s41565-018-0342-5 ↗
83. Design of amidobenzimidazole STING receptor agonists with systemic activity10.1038/s41586-018-0705-y ↗
84. Antivascular therapy of cancer: DMXAA10.1016/S1470-2045(03)01018-0 ↗
85. Structure-function analysis of STING activation by c [G (2′, 5′) pA (3′, 5′) p] and targeting by antiviral DMXAA10.1016/j.cell.2013.07.023 ↗
86. Mouse, but not human STING, binds and signals in response to the vascular disrupting agent 5, 6-dimethylxanthenone-4-acetic acid10.4049/jimmunol.1300097 ↗
87. Discovery of orally bioavailable phthalazinone analogues as an ENPP1 inhibitor for STING-mediated cancer immunotherapy10.1021/acs.jmedchem.3c01061 ↗
88. IUPHAR ECR review: the cGAS-STING pathway: novel functions beyond innate immune and emerging therapeutic opportunities10.1016/j.phrs.2024.107063 ↗
89. MV-626, a potent and selective inhibitor of ENPP1 enhances STING activation and augments T-cell mediated anti-tumor activity in vivo
90. Amplifying STING activation by cyclic dinucleotide–manganese particles for local and systemic cancer metalloimmunotherapy10.1038/s41565-021-00962-9 ↗
91. Zinc cyclic di-AMP nanoparticles target and suppress tumours via endothelial STING activation and tumour-associated macrophage reinvigoration10.1038/s41565-022-01225-x ↗
92. Mn2+ directly activates cGAS and structural analysis suggests Mn2+ induces a noncanonical catalytic synthesis of 2′ 3′-cGAMP10.1016/j.celrep.2020.108053 ↗
93. Metal‐cyclic dinucleotide nanomodulator‐stimulated STING signaling for strengthened radioimmunotherapy of large tumor
94. Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations10.1172/JCI79100 ↗
95. Self-DNA, STING-dependent signaling and the origins of autoinflammatory disease10.1016/j.coi.2014.10.009 ↗
96. Post-translational modifications of cGAS-STING: a critical switch for immune regulation10.3390/cells11193043 ↗
97. Traditional Chinese medicine compounds regulate autophagy for treating neurodegenerative disease: a mechanism review10.1016/j.biopha.2020.110968 ↗
98. Agonists and inhibitors of the STING pathway: potential agents for immunotherapy10.1002/med.21649 ↗
99. Activation of STING requires palmitoylation at the Golgi10.1038/ncomms11932 ↗
100. Targeting STING with covalent small-molecule inhibitors10.1038/s41586-018-0287-8 ↗